At present, the biomarkers of tumor size [7], histological grade [8], Ki67 [9], immunochemistry (IHC)-based subtype [8, 10, 11], and stromal tumor-infiltrating lymphocytes (sTILs) [12–14] are the clinicopathological (CP) factors used in predicting pCR partly due to their wide availability in routine clinical practice. Here, MKI67 is linked to neoplasm.